Actavis to Pay $170M for Reporting False Prices to Medicaid
In order for pharmaceutical products to be eligible for reimbursement from Medicaid, Texas law requires that manufacturers accurately report market prices to Medicaid. The Medicaid program then uses this drug-pricing information to determine the rates at which pharmacies are reimbursed for products.
The state's legal action against Actavis stems from a whistleblower lawsuit that was filed under seal by a Florida-based pharmacy, Ven-a-Care. The pharmacy pursued their claim after discovering Actavis reported artificially inflated prices to Medicaid for its drugs. The case against Actavis is the first to go to trial.
Read the news release about Actavis' verdict.
Read other coverage about pharmaceutical fraud:
- Pharmaceutical Company Will Pay $280M to Settle False Claims Allegations
- Irish Pharmaceutical Company and U.S. Subsidiary to Pay $203M for Off-Label Marketing
- Kos Pharmaceuticals Will Pay $41M to Settle Kickback, Off-Label Promotion Allegations
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- NAPA Becomes Exclusive Anesthesia Services Provider for Memorial Hospital
- Dr. Tiffany Denepitiya-Balicki Joins Greenwich Hospital
- Evergreen Medical, Bose Partner to Enhance Medical Device Testing Capabilities
- Covidien to Acquire GI Medical Device Company Given Imaging
- Endoscopy Center of Hanover Gastroenterology-NHRMC Physician Group Earns AAAHC Accreditation